<?xml version="1.0" encoding="UTF-8"?>
<p>At last, mannans should be mentioned. They have been reported to possess adjuvant-vaccine properties in clinical studies, probably mediated by its interaction with mannose receptors. Particularly, it has been shown that oxidized mannan-mucin 1 can be useful as an adjuvant in the breast cancer immunotherapy. Indeed, a 12â€“15 years follow-up has highlighted that it decreases the cancer recurrence rate and prolongs recurrence time, without inducing toxicity or adverse reactions [
 <xref rid="B124-vaccines-08-00468" ref-type="bibr">124</xref>]. 
</p>
